Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.

This open label randomized study aims to define the best protocol to be used with growth hormone in poor responders, with comparison performed to delineate which protocol offers the best cycle outcomes.

The patients were randomly allocated into four groups receiving growth hormone (GH) as an adjuvant therapy added to either long or short agonist protocol, miniflare or antagonist protocols.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Two-hundred eighty-seven poor responders were included.

What Was Measured

This open label randomized study aims to define the best protocol to be used with growth hormone in poor responders, with comparison performed to delineate which protocol offers the best cycle outcomes.

The subject headings attached to it are Clinical Protocols, Gonadotropin-Releasing Hormone, Growth Hormone, Luteolytic Agents, Menotropins, Oocytes and Outcome Assessment, Health Care.

The authors tagged it with the keywords Antagonist protocol, IVF/ICSI, long agonist protocol, miniflare protocol, poor responders and short agonist protocol.

What This Means in Plain Language

The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin).

The publication is from 2016 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.